65,155 Shares in Bioventus Inc. (NYSE:BVS) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Bioventus Inc. (NYSE:BVS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 65,155 shares of the company's stock, valued at approximately $684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.08% of Bioventus at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in shares of Bioventus in the fourth quarter valued at approximately $181,000. Charles Schwab Investment Management Inc. raised its stake in shares of Bioventus by 11.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock valued at $4,571,000 after acquiring an additional 45,182 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Bioventus by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock worth $202,000 after purchasing an additional 1,652 shares during the period. Vanguard Group Inc. increased its holdings in Bioventus by 18.7% in the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock valued at $25,852,000 after purchasing an additional 388,174 shares during the period. Finally, Barclays PLC raised its position in Bioventus by 31.0% during the 4th quarter. Barclays PLC now owns 66,337 shares of the company's stock worth $696,000 after purchasing an additional 15,683 shares during the last quarter. Institutional investors own 62.94% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BVS shares. Craig Hallum set a $15.00 price target on Bioventus and gave the company a "buy" rating in a research report on Wednesday, May 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th.

Bioventus Stock Performance

BVS stock remained flat at $6.71 during trading on Thursday. The company had a trading volume of 239,398 shares, compared to its average volume of 454,424. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.38. The business's fifty day simple moving average is $7.08 and its 200 day simple moving average is $9.20. The firm has a market capitalization of $551.19 million, a price-to-earnings ratio of -11.00 and a beta of 0.86.

Insider Buying and Selling at Bioventus

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the completion of the sale, the chief financial officer now owns 141,088 shares in the company, valued at $1,068,036.16. This represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 13,330 shares of company stock valued at $115,291. Corporate insiders own 32.90% of the company's stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.